Kevin DeGeeter
Stock Analyst at Oppenheimer
(2.79)
# 1,648
Out of 4,818 analysts
43
Total ratings
33.33%
Success rate
52.16%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.27 | +1,632.28% | 1 | Apr 19, 2022 | |
| ORIC ORIC Pharmaceuticals | Downgrades: Perform | n/a | $5.19 | - | 1 | Mar 22, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $3.69 | +551.29% | 4 | Feb 25, 2022 | |
| NVCR NovoCure | Upgrades: Outperform | $98 | $17.70 | +453.83% | 3 | Feb 2, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $18.95 | +559.80% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $1.66 | +984.34% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $3.44 | +452.33% | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $0.72 | - | 1 | Oct 1, 2021 | |
| PRTG Portage Biotech | Initiates: Outperform | $600 | $8.98 | +6,581.51% | 1 | Sep 21, 2021 | |
| PANW Palo Alto Networks | Maintains: Outperform | $75 → $79 | $168.32 | -52.96% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $44.13 | +251.23% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.37 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $3.97 | +529.72% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $255 | $0.23 | +109,624.61% | 1 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $1.47 | +122,348.98% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $40.05 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.81 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $7.14 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $0.31 | +16,117.97% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $4.15 | +21,586.75% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $7.47 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $21.84 | +930.22% | 1 | Apr 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $7.28 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.27 | - | 2 | Jan 4, 2017 |
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.27
Upside: +1,632.28%
ORIC Pharmaceuticals
Mar 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $5.19
Upside: -
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $3.69
Upside: +551.29%
NovoCure
Feb 2, 2022
Upgrades: Outperform
Price Target: $98
Current: $17.70
Upside: +453.83%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $18.95
Upside: +559.80%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $1.66
Upside: +984.34%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $3.44
Upside: +452.33%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $0.72
Upside: -
Portage Biotech
Sep 21, 2021
Initiates: Outperform
Price Target: $600
Current: $8.98
Upside: +6,581.51%
Palo Alto Networks
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $168.32
Upside: -52.96%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $44.13
Upside: +251.23%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $0.37
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $3.97
Upside: +529.72%
Apr 30, 2021
Initiates: Outperform
Price Target: $255
Current: $0.23
Upside: +109,624.61%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $1.47
Upside: +122,348.98%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $40.05
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.81
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $7.14
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $50
Current: $0.31
Upside: +16,117.97%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $4.15
Upside: +21,586.75%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $7.47
Upside: -
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $21.84
Upside: +930.22%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $7.28
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $2.27
Upside: -